Literature DB >> 9218854

Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia.

L M Best1, D J Haldane, G S Bezanson, S J Veldhuyzen van Zanten.   

Abstract

Resistance to antimicrobial agents is a major determinant of the efficacy of regimens to eradicate Helicobacter pylori. Clarithromycin (CLA) has become one of the most commonly used antibiotics for treatment of H pylori infection. In this study, the rate of primary resistance to CLA in H pylori isolated from patients was determined. One hundred sixty-two strains were recovered from patients before treatment. Strains were grown and inoculated onto Mueller-Hinton agar with 7% sheep blood. CLA epsilometer gradient agar diffusion test (E test) strips were used to test for susceptibility. Appropriate control organisms were tested to validate the assay. Plates were incubated at 37 degrees C in a microaerophilic atmosphere for up to five days. E test results were easy to interpret. Strains were considered resistant if the minimum inhibitory concentration (MIC) was 2 micrograms/mL or greater. Three strains were resistant (two strains with MIC 8 micrograms/mL and one strain with MIC 12 micrograms/mL) and 159 strains were sensitive (MICs ranged from less than 0.016 to 0.38 micrograms/mL). Ninety per cent of the strains had MICs of 0.023 micrograms/mL. Primary resistance was 1.8%. These susceptibility data support the use of CLA for the treatment of H pylori in the Nova Scotia population.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218854     DOI: 10.1155/1997/159637

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  8 in total

1.  Clarithromycin resistance in Helicobacter pylori and its clinical relevance.

Authors:  Hua-Xiang Xia; Xue-Gong Fan; Nicholas J Talley
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

Review 2.  Third-line rescue therapy for Helicobacter pylori infection.

Authors:  Rossella Cianci; Massimo Montalto; Franco Pandolfi; Giovan-Battista Gasbarrini; Giovanni Cammarota
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

3.  Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods.

Authors:  L M Best; D J M Haldane; M Keelan; D E Taylor; A B R Thomson; V Loo; C A Fallone; P Lyn; F M Smaill; R Hunt; C Gaudreau; J Kennedy; M Alfa; R Pelletier; S J O Veldhuyzen Van Zanten
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North.

Authors:  Amy L Morse; Karen J Goodman; Rachel Munday; Hsiu-Ju Chang; John Wi Morse; Monika Keelan; Janis Geary; Veldhuyzen van Zanten Sander
Journal:  Can J Gastroenterol       Date:  2013-12       Impact factor: 3.522

5.  A meta-analysis of the success rate of Helicobacter pylori therapy in Canada.

Authors:  Christopher Rodgers; Sander Veldhuyzen van Zanten
Journal:  Can J Gastroenterol       Date:  2007-05       Impact factor: 3.522

Review 6.  Diagnosis of Helicobacter pylori Using Invasive and Noninvasive Approaches.

Authors:  Amin Talebi Bezmin Abadi
Journal:  J Pathog       Date:  2018-05-22

7.  The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012.

Authors:  Chao-Hung Kuo; Fu-Chen Kuo; Huang-Ming Hu; Chung-Jung Liu; Sophie S W Wang; Yen-Hsu Chen; Ming-Chia Hsieh; Ming-Feng Hou; Deng-Chyang Wu
Journal:  Gastroenterol Res Pract       Date:  2012-06-27       Impact factor: 2.260

8.  Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.

Authors:  Tahir Shaikh; Carlo A Fallone
Journal:  Can J Gastroenterol Hepatol       Date:  2016-03-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.